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Abstract

Overdose due to opioid abuse is an ever increasing problem, especially in the United States, with the last few
years seeing a dramatic rise in the number of synthetic opioid-related deaths. The pure opioid antagonist
naloxone has been used in a clinical setting as an antidote to opioid overdose for decades. Recent data suggest
that the number of patients requiring multiple doses of naloxone is growing likely caused by the increased
number of intoxications with potent synthetic opioids such as fentanyl and its derivatives. Treating clinicians
in both emergency departments and pre-hospital settings should be aware that they may need to escalate to
higher doses of naloxone, with repeat doses or IV infusions required, when treating patients who have
overdosed on synthetic opioids. Moving forward, a combination of improved access to naloxone in a prehospital setting, an increase in community-based training, including the likely requirement of rapid or higher
dose naloxone administration for treatment of synthetic opioid overdose, and a better understanding of the
toxicology of high potency synthetic opioids, are required to decrease the number of fatalities stemming from
the current opioid crisis.
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Overdose due to opioid abuse is an ever increasing problem, especially in the United States, with
the last few years seeing a dramatic rise in the number of synthetic opioid-related deaths. The pure
opioid antagonist naloxone has been used in a clinical setting as an antidote to opioid overdose for
decades. Recent data suggest that the number of patients requiring multiple doses of naloxone is
growing likely caused by the increased number of intoxications with potent synthetic opioids such
as fentanyl and its derivatives. Treating clinicians in both emergency departments and pre-hospital
settings should be aware that they may need to escalate to higher doses of naloxone, with repeat
doses or IV infusions required, when treating patients who have overdosed on synthetic opioids.
Moving forward, a combination of improved access to naloxone in a pre-hospital setting, an
increase in community-based training, including the likely requirement of rapid or higher dose
naloxone administration for treatment of synthetic opioid overdose, and a better understanding of
the toxicology of high potency synthetic opioids, are required to decrease the number of fatalities
stemming from the current opioid crisis.
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The United States, sadly, is in the midst of an opioid epidemic. Data released by the National Center of Health
Statistics in December 2017 show that deaths from opioid overdose exceeded 42,000 in 2016, an increase of
more than 27% on 2015 [1] with increases seen for all
classes of opioids (Figure 1). Of greatest concern, however, is the rapid increase in the number of deaths from
synthetic opioids, such as fentanyl and its derivatives.
An agonist at all opioid receptors fentanyl is ﬁfty to a
hundred times more potent than morphine [2,3] with
respiratory depressant effects that peak in 5–15 min and
a dose-dependent duration of action [4]. Synthetic opioid deaths doubled from 9580 in 2015 to 19,413 in 2016
and contributed to the accelerated rise in opioid deaths
since 2013 (Figure 1) [1]. The trend appears unabated in
2017. In Ohio during January–February 2017 90% of the
281 unintentional overdose fatalities tested positive to
the presence of fentanyl with the majority of decedents
testing positive to more than one type of fentanyl derivative [5].
The US Government recently acknowledged the opioid crisis at both a state and federal level, with six states
taking the additional step of declaring the issue a state of
emergency [6]. Both Alaska and Maryland speciﬁcally
acknowledged the role synthetic opioids are playing, and
ﬁve of the six states used their emergency declaration to

promote an increase in access to the opioid antidote
naloxone [6]. The approaches taken to promote this
improved access to naloxone vary greatly by state and
local area. Some of the programs introduced include: the
training and education of emergency medical services,
law enforcement personnel and lay-persons; supply of
naloxone to emergency medical services and law
enforcement agencies; lay-person access to naloxone via
pharmacy without a prescription; and programs to
directly supply naloxone to addicts upon institutional
release [6,7].
Clinicians have used the opioid antagonist naloxone
as an antidote to opioid overdose for decades. As a competitive antagonist at the m-opioid receptor it effectively
reverses clinical signs of opioid intoxication. However,
naloxone can precipitate withdrawal effects in opioidaddicted individuals. The US Food and Drug Administration (FDA) approved its use as an intravenous, intramuscular, or subcutaneous injection of naloxone
hydrochloride in 1971, and more recently in the form of
the EvzioÒ auto-injector in 2014, designed for intramuscular or subcutaneous administration, and NarcanÒ
Nasal Spray, designed for intranasal administration, in
2015.
The recent approval and increased availability of
intranasal naloxone products has altered the pre-hospital
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Figure 1. Drug overdose deaths in the United States, 1999–2016, by opioid category. Deaths involving more than one drug may be
counted in more than one category. Data taken from the NCHS Data Brief, December 2017 [1].

care setting in the past few years. Lay-persons are able to
regularly administer these products as they eliminate the
risk of needle-stick injury. However, the prices of both
NarcanÒ Nasal Spray (»$US135 for a two pack) [8] and
the Evzio auto-injector (»$US3800 for a two pack) [8]
are hindersome to their use. Claims from the NarcanÒ
Nasal Spray manufacturer that the drug is affordable as
“80% of current prescriptions have a co-pay of $20 or
less” [9] are unlikely to accurately represent the current
pricing situation as opioid addicts who are not able to
purchase naloxone due to its inhibitive cost are not
reﬂected in these statistics. Continuing to ease access to
naloxone, including a decrease in price, allowing nonprescription supply and providing training for both laypersons and advanced life support providers is a critical
step in the attempt to decrease the number of deaths
stemming from the opioid epidemic.
US National Emergency Medical Service data show
that the number of patients requiring multiple naloxone

doses is trending upwards [10] likely as a result of
increasing intoxication with synthetic opioids. Literature
evidence of cases involving higher than usual doses of
naloxone is summarized in Tables 1 (case studies) and 2
(retrospective case series). Gussow 2016 suggested that
protocols starting with very low doses or naloxone
(<0.4 mg) may need to be rethought, providing anecdotal evidence that patients with presumed carfentanil
exposure required up to 18 mg of naloxone to reverse
the effects of opioid intoxication [11]. The general conversational nature of this report with no analytical analysis or data provided shows the importance of ensuring
unusual cases are fully reported in the literature with
naloxone doses and full toxicological blood and urine
screening results in order to better inform changes to
naloxone dosage protocols.
The FDA currently recommends an initial dose of
0.4–2 mg of naloxone via IV or IM, with some emergency medical service protocols recommending the

Table 1. Case studies involving higher than usual doses of naloxone in patients with synthetic opioid intoxication.
Ref.
Patient
[12] 23-year-old female,
unresponsive,
4 breaths/min
[13] 36-year-old male, altered
mental status, pinpoint
pupils, GCS = 6

Drug
U-47700 insufﬂated and IV

Naloxone dose
2 mg IN – no response; 2 mg IV - response
(4 mg total)

Outcome
Discharged next day; LC-MS drug
conﬁrmation

Vaping “synthetic opium”
shown to contain
acetylfentanyl

[14] 24-year-old male,
hypotension, hypoxic
respiratory failure

Street purchased
hydrocodone/
acetaminophen tablets
shown to contain fentanyl

2 mg IV – awoke but eventually mental status Admitted to ICU; Identity of drug
declined; 2 mg IV – again roused but
determined through website of sale
mental status declined; 2 mg IV followed by
1.5mg/hour infusion (>7.5 mg total)
2 mg IN + 1 mg IV – no signiﬁcant response Eighteen further patients over eight days,
(3 mg total)
one death, 3/18 received 5 mg
naloxone total bolus dose, 4/18
received a naloxone infusion
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Table 2. Retrospective case series involving higher than usual doses of naloxone to treat patients with suspected synthetic opioid
intoxication.
Ref.
Study description
Naloxone administered
[15] Observational case series; Chicago, IL; ED data; Twenty-six cases; 0.4–12 mg IV naloxone;
Opioid overdoses 5 April–6 Dec
average 3.36 mg
[10] Data analysis of NEMSIS 2012–2015; naloxone
use only; comparison of single vs. multiple
naloxone administration (MNA)
[16] Survey study; April 2016 MA; adults who had
used opioids (<2 months) and witnessed or
survived an opioid overdose (<6 months)

2012: 95,012 patients received naloxone;
14.49% MNA
2015: 173,016 patients received naloxone;
18.24% MNA
83% of survey respondents reported that
2 naloxone doses (likely 2 mg/2ml) were
required in cases of suspected fentanyl
overdose

lower end of this dosing regimen [17,18]. However, in
cases of an unknown intoxication with opioids resulting
in poor or incomplete response to naloxone, or known
intoxication with synthetic opioids, clinical staff may
need to escalate to higher doses more quickly than they
would have previously with opioids such as heroin. In
addition, multiple doses or intravenous infusions are
often required as fentanyl and its derivatives have a longer biologically active half-life than naloxone [4].
In the face of the rising opioid epidemic, the obvious
difﬁculty facing clinical staff is that often they do not
know identity of the opioid causing the intoxication. A
number of illicit opioids, including fentanyl, do not produce a positive result on a standard drug urine screen
and staff have to rely solely on the opioid toxidrome to
identify cases of suspected opioid intoxication. Adding
to this complexity is the fact that the 200 known synthetic derivatives of fentanyl, some of which are up to
10,000 times more potent than morphine, are increasingly sold as heroin or in combination with heroin without the knowledge of the user [19,20]. We suggest
beginning with smaller doses of naloxone (0.4 mg IV),
followed by a rapid escalation to higher doses (2 mg) if
no response is observed within 2–3 min.
Pre-hospital settings would likely require similar protocols with lay-persons or emergency medical personnel
administering naloxone via the intramuscular or intranasal route. It is therefore important to ensure an
explicit explanation of the likely higher doses of naloxone required for treatment of synthetic opioid in education and training programs. Additionally, treating staff
need access to adequate volumes of naloxone to deal
with this eventuality.
Moving forward we require improved access to naloxone in the pre-hospital setting, increased communitybased training including the likely requirement of rapid/
higher dose naloxone administration for treatment of
synthetic opioid overdose, and a better understanding of
the toxicology of high potency synthetic opioids, to
reduce the number of fatalities stemming from the current opioid crisis.

Summary of ﬁndings
6/26 patients required >6 mg IV naloxone; 0.4 mg
effectively reversed patient toxicity in only 15% of
ED cases; even with some initial doses of 2 mg IV no
patients experienced signiﬁcant withdrawal
MNA increased 25.8% from 2012 to 2015; odds of
MNA were the highest in north-eastern US, which is
consistent with increased use of fentanyl; no data on
administration route
»2/3 of opioid overdose deaths in south-eastern MA
(Oct 2014–Mar 2015) involved fentanyl [44% in Oct
2014 to 76% in Mar 2015]
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